Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0019 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Giardia lamblia | DINP protein human, muc B family | 0.0019 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0013 | 0.2351 | 0.2351 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0013 | 0.2351 | 0.2351 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 1 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 1 | 1 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0019 | 1 | 1 |
Echinococcus granulosus | dna polymerase eta | 0.0019 | 1 | 1 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0019 | 1 | 1 |
Echinococcus granulosus | dna polymerase kappa | 0.0019 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0019 | 1 | 0.5 |
Schistosoma mansoni | DNA polymerase eta | 0.0019 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0019 | 1 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0013 | 0.2351 | 0.2351 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0019 | 1 | 1 |
Toxoplasma gondii | cytochrome p450 superfamily protein | 0.0011 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0011 | 0 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0019 | 1 | 1 |
Echinococcus multilocularis | dna polymerase kappa | 0.0019 | 1 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 1 | 1 |
Echinococcus multilocularis | dna polymerase eta | 0.0019 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0013 | 0.2351 | 0.2351 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0019 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 1 | 1 |
Mycobacterium leprae | putative cytochrome p450 | 0.0011 | 0 | 0.5 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0019 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0019 | 1 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0019 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0013 | 0.2351 | 0.2351 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 2 uM | Antiviral activity against human peripheral blood mononuclear cells, infected with HIV-1(strain LAV) | ChEMBL. | 1720175 |
EC50 (functional) | = 9.1 uM | Antiviral activity against human peripheral blood mononuclear cells, infected with HIV-2(strain ROD-2) | ChEMBL. | 1720175 |
EC50 (functional) | > 100 uM | Antiviral activity against Vero cells, infected with HSV-1 | ChEMBL. | 1720175 |
IC50 (ADMET) | = 25.7 uM | The compound was tested for toxicity in Vero cells | ChEMBL. | 1720175 |
IC50 (functional) | > 100 uM | The compound was tested for toxicity in peripheral blood mononuclear cells | ChEMBL. | 1720175 |
IC50 (binding) | > 100 uM | Inhibition of HIV-1 reverse transcriptase from peripheral blood mononuclear cells | ChEMBL. | 1720175 |
IC50 (binding) | > 100 uM | Inhibitory activity against DNA polymerase-alpha derived from peripheral blood mononuclear cells | ChEMBL. | 1720175 |
IC50 (binding) | > 100 uM | Inhibition of HIV-1 reverse transcriptase from peripheral blood mononuclear cells | ChEMBL. | 1720175 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.